Fatih M. Uckun

Dr. Fatih M. Uckun

Ares Pharmaceuticals, LLC, St. Paul, Minnesota, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSM Smith
M Smith
DAD Arthur
D Arthur
BCB Camitta
B Camitta
ACA J Carroll
A J Carroll
WCW Crist
W Crist
RUR Ungerleider
R Ungerleider
PURPOSE: To define more uniform criteria for risk-based treatment assignment for children with acute lymphoblastic leukemia (ALL), the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) sponsored a workshop in September 1993. Participants included representatives from the Childrens Cancer Group (CCG), Pediatric Oncology Group (POG), Dana-Farber Cancer Institute (DFCI), St Jude Children's Research Hospital (SJCRH), and the CTEP. METHODS: Workshop participants presented and reviewed data from ALL clinical trials, using weighted averages to combine outcome data from different groups. RESULTS: For patients with B-precursor (ie, non-T, non-B) ALL, the standard-risk category (4-year event-free survival [EFS] rate, approximately 80%) will include patients 1 to 9 years of age with a WBC count at diagnosis less than 50,000/microL. The remaining patients will be classified as having high-risk ALL (4-year EFS rate, approximately 65%). For patients with T-cell ALL, different treatment strategies have yielded different conclusions concerning the prognostic significance of T-cell immunophenotype. Therefore, some groups/institutions will classify patients with T-cell ALL as high risk, while others will assign risk for patients with T-cell ALL based on the uniform age/WBC count criteria. Workshop participants agreed that the risk category of a patient may be modified by prognostic factors in addition to age and WBC count criteria, and that a common set of prognostic factors should be uniformly obtained, including DNA index (DI), cytogenetics, early response to treatment (eg, day-14 bone marrow), immunophenotype, and CNS status. CONCLUSIONS: The more uniform approach to risk-based treatment assignment and to collection of specific prognostic factors should increase the efficiency of future ALL clinical research.

4 June 1998 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JNJames B. Nachman
James B. Nachman
HSHarland N. Sather
Harland N. Sather
MSMartha G. Sensel
Martha G. Sensel
MTMichael E. Trigg
Michael E. Trigg
JCJoel M. Cherlow
Joel M. Cherlow
PGPaul S. Gaynon
Paul S. Gaynon
Children with high-risk acute lymphoblastic leukemia (ALL) who have a slow response to initial chemotherapy (more than 25 percent blasts in the bone marrow on day 7) have a poor outcome despite intensive therapy. We conducted a randomized trial in which such patients were treated with either an augmented intensive regimen of post-induction chemotherapy or a standard regimen of intensive post-induction chemotherapy.

5 March 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KCKaimin Cai
Kaimin Cai
XHXi He
Xi He
ZSZiyuan Song
Ziyuan Song
QYQian Yin
Qian Yin
YZYanfeng Zhang
Yanfeng Zhang
JCJianjun Cheng
Jianjun Cheng

10 February 1995 in Science
Verified
Journal Article
Closed access
PDF file
Fatih M. UckunFatih M. Uckun
Fatih M. Uckun
WEW. E. Evans
W. E. Evans
CFC. J. Forsyth
C. J. Forsyth
KWK. G. Waddick
K. G. Waddick
LTL. Tuel-Ahlgren
L. Tuel-Ahlgren
DMD. E. Myers
D. E. Myers
B-cell precursor (BCP) leukemia is the most common form of childhood cancer and the second most common form of acute leukemia in adults. Human BCP leukemia was treated in a severe combined immunodeficient mouse model by targeting of the tyrosine kinase inhibitor Genistein (Gen) to the B cell-specific receptor CD19 with the monoclonal antibody B43. The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death. At less than one-tenth the maximum tolerated dose more than 99.999 percent of human BCP leukemia cells were killed, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia. The B43-Gen immunoconjugate might be useful in eliminating leukemia cells in patients who have failed conventional therapy.

1 November 1997 in Cancer
Verified
Journal Article
Closed access
PDF file
PGPaul S. Gaynon
Paul S. Gaynon
ADAnish A. Desai
Anish A. Desai
BBBruce C. Bostrom
Bruce C. Bostrom
RHRaymond J. Hutchinson
Raymond J. Hutchinson
BLBeverly J. Lange
Beverly J. Lange
Fatih M. UckunFatih M. Uckun
Fatih M. Uckun

1 April 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SMSandeep Mahajan
Sandeep Mahajan
SGSutapa Ghosh
Sutapa Ghosh
ESElise A. Sudbeck
Elise A. Sudbeck
YZYaguo Zheng
Yaguo Zheng
SDSuzanne Downs
Suzanne Downs
Fatih M. UckunFatih M. Uckun
Fatih M. Uckun
In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton's tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizing properties, we have constructed a three-dimensional homology model of the BTK kinase domain. Our modeling studies revealed a distinct rectangular binding pocket near the hinge region of the BTK kinase domain with Leu460, Tyr476, Arg525, and Asp539 residues occupying the corners of the rectangle. The dimensions of this rectangle are approximately 18 x 8 x 9 x 17 A, and the thickness of the pocket is approximately 7 A. Advanced docking procedures were employed for the rational design of leflunomide metabolite (LFM) analogs with a high likelihood to bind favorably to the catalytic site within the kinase domain of BTK. The lead compound LFM-A13, for which we calculated a Ki value of 1.4 microM, inhibited human BTK in vitro with an IC50 value of 17.2 +/- 0.8 microM. Similarly, LFM-A13 inhibited recombinant BTK expressed in a baculovirus expression vector system with an IC50 value of 2.5 microM. The energetically favorable position of LFM-A13 in the binding pocket is such that its aromatic ring is close to Tyr476, and its substituent group is sandwiched between residues Arg525 and Asp539. In addition, LFM-A13 is capable of favorable hydrogen bonding interactions with BTK via Asp539 and Arg525 residues. Besides its remarkable potency in BTK kinase assays, LFM-A13 was also discovered to be a highly specific inhibitor of BTK. Even at concentrations as high as 100 micrograms/ml (approximately 278 microM), this novel inhibitor did not affect the enzymatic activity of other protein tyrosine kinases, including JAK1, JAK3, HCK, epidermal growth factor receptor kinase, and insulin receptor kinase. In accordance with the anti-apoptotic function of BTK, treatment of BTK+ B-lineage leukemic cells with LFM-A13 enhanced their sensitivity to ceramide- or vincristine-induced apoptosis. To our knowledge, LFM-A13 is the first BTK-specific tyrosine kinase inhibitor and the first anti-leukemic agent targeting BTK.